Oxford Biomedica (LON:OXB) Share Price Crosses Below 200 Day Moving Average – Time to Sell?

Oxford Biomedica plc (LON:OXB)’s stock price passed below its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of GBX 664.67 and traded as low as GBX 600. Oxford Biomedica shares last traded at GBX 603.19, with a volume of 228,335 shares changing hands.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on OXB. Royal Bank Of Canada decreased their price objective on shares of Oxford Biomedica from GBX 1,170 to GBX 1,140 and set an “outperform” rating for the company in a research report on Wednesday, June 24th. Jefferies Financial Group reissued a “buy” rating and issued a GBX 8.27 target price on shares of Oxford Biomedica in a report on Tuesday, June 2nd. Six research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, Oxford Biomedica presently has an average rating of “Buy” and an average price target of GBX 633.38.

Oxford Biomedica Trading Down 4.3%

The company has a market cap of £706.86 million, a price-to-earnings ratio of -21.69 and a beta of 1.12. The company has a quick ratio of 1.67, a current ratio of 2.20 and a debt-to-equity ratio of 162.16. The business’s fifty day simple moving average is GBX 614.75 and its two-hundred day simple moving average is GBX 664.62.

About Oxford Biomedica

Oxford Biomedica (LSE: OXB) is a quality and innovation-led cell and gene therapy CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world.

One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies. The Company collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors.